Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Randomised controlled trial.
Follow up period:
Centres in 11 European countries (including Turkey) and Canada; recruitment from October 2002 to July 2003.
541 people over the age of 50 years diagnosed with Parkinson’s disease (PD; UK PD Society Brain Bank criteria) and mild to moderate PD related dementia (DSM-IV; Mini Mental State Examination (MMSE) score 10–24). Exclusion criteria were: non-PD neurodegeneration; unstable medical comorbidity, disability, or dementia not related to PD; active, uncontrolled seizures; prior major depressive disorder; or use of anticholinergic drugs or cholinesterase inhibitor in previous month.
Rivastigmine (3–12 mg daily) titrated to maximum well tolerated dose over 16 week period, or placebo.
Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) score (range 0–70, higher score indicates greater impairment); Alzheimer’s Disease Cooperative Study—Clinician’s Global Impression of Change (ADCS-CGIC; ranges from 1 (marked improvement) to 7 (marked worsening)); adverse events.
Patient follow up:
Rivastigmine significantly improved cognitive performance compared with placebo by week 24 (mean change in ADAS-cog score: −2.1 with rivastigmine v +0.7 with placebo; p<0.001). Rivastigmine significantly increased clinician rated global improvement by week 24 compared with placebo (mean ADCS-CGIC score: 3.8 with rivastigmine v 4.3 with placebo; p = 0.007). However, rivastigmine was associated with significantly more nausea (29% v 11.2%; p<0.001), vomiting (16.6% v 1.7%; p<0.001), and tremor (10.2% v 3.9%, p = 0.01) than placebo. Serious adverse events were similar in both groups (13.0% with rivastigmine v 14.5% with placebo, p = 0.69).
Rivastigmine produces modest but significant improvements in dementia associated with PD. Rivastigmine use is associated with an increase in nausea, vomiting, and tremor.
Since the approval of cholinesterase inhibitors (ChE-Is) for symptomatic treatment of Alzheimer’s disease (AD), both clinicians and pharmaceutical companies have been keen to understand whether people with other types of dementia or cognitive impairment will also benefit. There has been enthusiasm for administration of ChE-Is to people with dementia with Lewy bodies.1,3 Previous studies on Parkinson’s disease (PD) had much smaller samples of at most 14 participants, and results raised questions about whether treatment with a cholinergic drug would secondarily worsen dopaminergic tone in those already at a primary dopaminergic disadvantage.4,7
Although pharma-driven, the study design and methods used by Emre et al are fairly transparent. The study population was allowed to continue medication management as indicated for their parkinsonism and psychosis, and therefore represents a naturalistic sample of people with dementia in PD (PDD). One in 19 people with PDD who received rivastigmine had a clinically significant improvement on global measures of function (NNT = 19; compared with NNT of AD patients = 12).8 One in six people with PDD who received rivastigmine experienced nausea (v one in 12 people with AD).8 More people with PDD developed worsening tremors than responded positively—the absence of post-treatment Unified Parkinson’s Disease Rating Scale (UPDRS) scores for tremor is curious.
When contemplating the use of rivastigmine for PDD, the frequency of nausea should be borne in mind. In addition, the clinician should set realistic expectations by specifying target symptoms to evaluate during medication trial and noting that people with AD have a higher response rate. The use of rivastigmine in people with tremor dominant PD or a Hoehn and Yahr scale score >3 would not be recommended, as this group was much less tolerant of the most frequent adverse events.
Emre et al have made an important contribution to the literature and seem to confirm concerns that some aspects of cholinergic treatment may not be beneficial to patients with PDD.
For correspondence: Dr Murat Emre, Istanbul Tip Fakültesi, Nöroloji Anabilim Dali, 34390 Capa, Istanbul, Turkey
Sources of funding: Novartis.